Navigation Links
NIH awards grant to Banner Alzheimer's Institute for major prevention study
Date:9/18/2013

In collaboration with the National Institutes of Health (NIH), Banner Alzheimer's Institute (BAI) announces a major prevention trial to evaluate a treatment in cognitively healthy older adults at the highest known genetic risk for developing Alzheimer's disease at older ages. An NIH grant, expected to total $33.2 million, will support this research. (NIA support: AG 046150-01)

The study is part of the Alzheimer's Prevention Initiative (API), an international collaboration led by BAI to accelerate the evaluation of promising but unproven prevention therapies. It will test an anti-amyloid treatment in about 650 adults, ages 60-75, who have two copies of the apolipoprotein E (APOE4) gene, the major genetic risk factor for late-onset Alzheimer's. None of the participants will have impairments in memory or thinking at the time they enter the study.

"Once again, we are extremely grateful to the NIH for the opportunity to help accelerate the evaluation of treatments to prevent the clinical onset of Alzheimer's and find ones that work as soon as possible," said Dr. Eric M. Reiman, BAI Executive Director. "This trial will allow us to extend our work to individuals at greatest risk at older ages."

The randomized, placebo-controlled trial, which will take place at BAI and other U.S. sites, will test the treatment's ability to stave off the memory and thinking declines associated with Alzheimer's. It will also assess the treatment's effects on different brain imaging and cerebrospinal fluid measurements of the disease. The specific compound to be evaluated has not been decided.

The trial will test what is often called the amyloid hypothesis, which suggests that accumulation of the protein amyloid in the brain plays a key role in the disease's progression. Major funding from philanthropy and industry will also support the trial, and its leaders expect to provide data and biological samples to the research community after the trial's conclusion to help in the scientific fight against Alzheimer's.

Individuals in the study will learn their APOE4 status. To help them prepare for this information, BAI has convened an expert committee to develop a comprehensive genetic testing and disclosure plan and to assess the impact of this disclosure during the trial.

"Under the National Plan to Address Alzheimer's Disease, our goal is to prevent and effectively treat the disorder by 2025," said Dr. Neil Buckholtz, of the National Institute on Aging, which leads Alzheimer's research at the National Institutes of Health.

"We are delighted to support Dr. Reiman, Dr. Tariot and their team in this innovative clinical trial aimed at preventing the onset and progression of this devastating disease."

The research is intended to complement API's initial trial, which is primarily focused in Colombia and involves about 300 people from an extended family with a rare genetic mutation that typically triggers Alzheimer's symptoms around age 45. That work also is focusing on an anti-amyloid therapy and its potential in slowing or blocking the disease while preserving cognitive abilities. The investigation, including a smaller U.S. companion study, dovetails with prevention trials that have been planned or started by other research groups during the past 16 months.

"We are now looking at potential treatments to prevent both the early and late onset forms of the disease," said Dr. Pierre N. Tariot, BAI Director. "This kind of comprehensive approach could prove the tipping point in our long, arduous effort to find a way to end this devastating disease."

The new trial will draw participants mainly from the Alzheimer's Prevention Registry, an online community of people who are committed to helping in the fight against Alzheimer's. The Registry provides regular updates on the latest scientific advances, as well as information on overall brain health. To overcome one of the biggest obstacles to clinical research, the Registry supports enrollment in a variety of Alzheimer's prevention studies within members' communities.

Alzheimer's is a debilitating and incurable disease that affects more than 5.2 million Americans, with a new diagnosis every 68 seconds. Without the discovery of successful prevention therapies, the number of U.S. cases is projected to nearly triple by 2050.


'/>"/>

Contact: Kate Enos
kenos@gymr.com
202-745-5071
GYMR
Source:Eurekalert

Related medicine news :

1. T.E.N. Announces Nominees for the 2013 ISE® North America Awards
2. Tri-County Electric People Fund Awards Grant To Eagle Village
3. Parent Magic Inc's "Surviving Your Adolescents" Wins Gold Award in National Parenting Publications Awards 2013
4. Jose’s Hands to Host The World’s First Red Carpet Medical Mission Awards in Miami Beach
5. Extended-Car-Warranty.com Awards CARCHEX with the 2013 Gold Award after Conducting Reviews of Extended Auto Warranty Companies
6. Jury Awards Sacramento Woman $680,000 for Auto Accident Caused by Distracted Driving
7. USHEALTH Advisors, LLC Announces its Selection as Bronze Stevie® Award Winner in 2013 International Business Awards
8. It Works! Global Awards Kami Dempsey With "Black Diamond" Title
9. Kids II® Wins Thirteen 2013 American Inhouse Design Awards
10. ASTRO awards $34,500 in individual grants to top researchers presenting at the 2013 Annual Meeting
11. Entries Now Open for HREI Insights Awards™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Cosmetic Town, an online plastic surgery community, ... forum section was recently revamped and upgraded to allow even more interaction between doctors ... the country. , According to the senior editor of Cosmetic Town, “We are excited ...
(Date:4/28/2016)... ... April 28, 2016 , ... Horizon ... collaborating with doctors and hospitals to make transformative changes in how health care ... therapy minds this week in discussing breakthroughs in cellular medicine to treat disease. ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... USA Medical Card reminds us that May ... (CDC), a stroke is the fourth leading cause of death in the United States; someone ... almost a quarter of them in individuals under 65 years old. A stroke is ...
(Date:4/28/2016)... PA (PRWEB) , ... April 28, 2016 , ... ... Browne, M.D. has been named a Top Doc in Physical Medicine and Rehabilitation ... conjunction with Castle Connolly Medical, Ltd. by randomly surveying physicians and medical leadership ...
(Date:4/28/2016)... ... April 28, 2016 , ... Denise McCormick Baich had written poetry dating back to her ... again much like a tsunami and took on a more spiritual tone. The desire to ... to do more with it than just file it away. Friends would ask her how ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
(Date:4/27/2016)... April 27, 2016 Transparency Market ... Devices Market - Global Industry Analysis, Size, Share, Growth, ... report, the global skincare devices market was valued at ... expand at a CAGR of 10.1% from 2015 to ... Browse the full Skincare Devices Market (Treatment Device - ...
Breaking Medicine Technology: